GlassScriptPhysician profile
Joshua Rosenberg
NPI 1629264924
$881,261.56
in general payments reported to CMS, 2019-2025
22 companies · $219K in 2025
The $219K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186K · 2020: $76K · 2021: $54K · 2022: $87K · 2023: $120K · 2024: $139K · 2025: $219K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $331K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $80K · Travel and Lodging: $41K · Food and Beverage: $13K · Consulting Fee: $8,043 · Honoraria: $4,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $331,072.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $80,180.00 |
| Travel and Lodging | $41,125.13 |
| Food and Beverage | $13,196.38 |
| Consulting Fee | $8,042.50 |
| Honoraria | $4,335.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $327,242.88 | 2021-2025 | Avycaz, Teflaro, Dalvance |
| Merck Sharp & Dohme LLC | $173,009.35 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Allergan, INC. | $121,567.63 | 2019-2022 | |
| Shionogi INC | $101,411.25 | 2019-2025 | Fetroja |
| Aimmune Therapeutics, INC. | $75,595.11 | 2024-2025 | Zenpep, Vowst |
| La Jolla Pharmaceutical Company | $31,059.57 | 2021-2025 | Xerava, Xacduro, Zevtera |
| Sanofi Pasteur INC. | $24,740.54 | 2019-2022 | |
| Tetraphase Pharmaceuticals, INC. | $22,962.56 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $1,031.14 | 2020-2022 | |
| Melinta Therapeutics, LLC | $708.11 | 2019-2025 | Rezzayo |
| Pfizer INC. | $537.23 | 2019-2020 | |
| Csl Behring | $382.42 | 2022-2025 | Kcentra |
| Genzyme Corporation | $244.32 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $214.11 | 2021-2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $124.53 | 2019 | |
| Gilead Sciences, INC. | $123.72 | 2022 | |
| Accelerate Diagnostics INC. | $64.55 | 2023 | |
| Terumo Medical Corporation | $33.44 | 2020 | |
| Irhythm Technologies, INC. | $29.60 | 2024 | Zio Xt Patch, Zio Monitor |
| Actelion Pharmaceuticals US, INC. | $26.72 | 2022 | |
| Chiesi USA, INC. | $17.78 | 2024 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.